Identification
- Composition (DCI)
- lévodopabenzérazide
- Manufacturer
- ROCHE S.A
- ATC code
- N04BA02
- Presentation
- Boîte de 100 ( Lévodopa : 200 MG | Bensérazide : 50 MG)
- Schedule / Reimb.
- A
- Hospital price
- 185.50 MAD
Indications
Maladie de Parkinson Madopar est indiqué pour le traitement du syndrome parkinsonien sous toutes ses formes; exception: le syndrome parkinsonien d'origine médicamenteuse. Syndrome des jambes sans repos Madopar est indiqué pour le traitement du syndrome des jambes sans repos idiopathique et symptomatique (Restless Legs Syndrome, RLS). Source : Compendium.ch - Date : 20 octobre 2025
Find an open pharmacy
On-call pharmacies near you
About MADOPAR 250 MG
MADOPAR 250 MG is marketed in Morocco by ROCHE S.A and is among the pharmaceutical specialties referenced by the Ministry of Health.
For any question about the use, effects, or drug interactions of MADOPAR 250 MG, consult your doctor or pharmacist. This information is provided for educational purposes and does not replace medical advice.
Frequently Asked Questions about MADOPAR 250 MG
Answers to common questions from Moroccan patients about this drug.